133 related articles for article (PubMed ID: 12646790)
1. Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART.
Morlese J; Teo IA; Choi JW; Gazzard B; Shaunak S
AIDS; 2003 Mar; 17(5):679-83. PubMed ID: 12646790
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection.
Brussel A; Mathez D; Broche-Pierre S; Lancar R; Calvez T; Sonigo P; Leibowitch J
AIDS; 2003 Mar; 17(5):645-52. PubMed ID: 12646786
[TBL] [Abstract][Full Text] [Related]
3. Reliable and reproducible LightCycler qPCR for HIV-1 DNA 2-LTR circles.
Teo IA; Morlese J; Choi JW; Shaunak S
J Immunol Methods; 2002 Dec; 270(1):109-18. PubMed ID: 12379343
[TBL] [Abstract][Full Text] [Related]
4. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections.
Nunnari G; Otero M; Dornadula G; Vanella M; Zhang H; Frank I; Pomerantz RJ
AIDS; 2002 Jan; 16(1):39-45. PubMed ID: 11741161
[TBL] [Abstract][Full Text] [Related]
5. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
Gandhi RT; Coombs RW; Chan ES; Bosch RJ; Zheng L; Margolis DM; Read S; Kallungal B; Chang M; Goecker EA; Wiegand A; Kearney M; Jacobson JM; D'Aquila R; Lederman MM; Mellors JW; Eron JJ;
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):229-35. PubMed ID: 22083073
[TBL] [Abstract][Full Text] [Related]
6. Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients.
Bona R; Baroncelli S; D'Ettorre G; Andreotti M; Ceccarelli G; Filati P; Leone P; Blasi M; Michelini Z; Galluzzo CM; Mallano A; Vullo V; Cara A
AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1365-9. PubMed ID: 23802629
[TBL] [Abstract][Full Text] [Related]
7. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
Delaugerre C; Charreau I; Braun J; Néré ML; de Castro N; Yeni P; Ghosn J; Aboulker JP; Molina JM; Simon F;
AIDS; 2010 Sep; 24(15):2391-5. PubMed ID: 20683319
[TBL] [Abstract][Full Text] [Related]
8. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
[TBL] [Abstract][Full Text] [Related]
10. Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker.
Bushman F
AIDS; 2003 Mar; 17(5):749-50. PubMed ID: 12646799
[No Abstract] [Full Text] [Related]
11. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA.
Cara A; Vargas J; Keller M; Jones S; Mosoian A; Gurtman A; Cohen A; Parkas V; Wallach F; Chusid E; Gelman IH; Klotman ME
Virology; 2002 Jan; 292(1):1-5. PubMed ID: 11878902
[TBL] [Abstract][Full Text] [Related]
12. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
Hatano H; Strain MC; Scherzer R; Bacchetti P; Wentworth D; Hoh R; Martin JN; McCune JM; Neaton JD; Tracy RP; Hsue PY; Richman DD; Deeks SG
J Infect Dis; 2013 Nov; 208(9):1436-42. PubMed ID: 23975885
[TBL] [Abstract][Full Text] [Related]
13. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.
Graf EH; Mexas AM; Yu JJ; Shaheen F; Liszewski MK; Di Mascio M; Migueles SA; Connors M; O'Doherty U
PLoS Pathog; 2011 Feb; 7(2):e1001300. PubMed ID: 21383972
[TBL] [Abstract][Full Text] [Related]
14. Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy.
Zhu W; Jiao Y; Lei R; Hua W; Wang R; Ji Y; Liu Z; Wei F; Zhang T; Shi X; Wu H; Zhang L
PLoS One; 2011; 6(6):e21081. PubMed ID: 21687638
[TBL] [Abstract][Full Text] [Related]
15. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.
Dornadula G; Zhang H; VanUitert B; Stern J; Livornese L; Ingerman MJ; Witek J; Kedanis RJ; Natkin J; DeSimone J; Pomerantz RJ
JAMA; 1999 Nov; 282(17):1627-32. PubMed ID: 10553788
[TBL] [Abstract][Full Text] [Related]
16. Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy.
Ibáñez A; Clotet B; Martínez MA
Virology; 2001 Mar; 282(1):1-5. PubMed ID: 11259184
[TBL] [Abstract][Full Text] [Related]
17. Quantitative PCR used to assess HIV-1 integration and 2-LTR circle formation in human macrophages, peripheral blood lymphocytes and a CD4+ cell line.
Friedrich B; Li G; Dziuba N; Ferguson MR
Virol J; 2010 Dec; 7():354. PubMed ID: 21129188
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
Dornadula G; Nunnari G; Vanella M; Roman J; Babinchak T; DeSimone J; Stern J; Braffman M; Zhang H; Pomerantz RJ
J Infect Dis; 2001 Jun; 183(11):1682-7. PubMed ID: 11343220
[TBL] [Abstract][Full Text] [Related]
19. Lack of evidence for prolonged double-long terminal repeat episomal HIV DNA stability in vivo.
Chavez HH; Tran TA; Dembele B; Nasreddine N; Lambotte O; Gubler B; le Névot E; Delfraissy JF; Taoufik Y
J Acquir Immune Defic Syndr; 2007 Jun; 45(2):247-9. PubMed ID: 17527094
[No Abstract] [Full Text] [Related]
20. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
Saitoh A; Hsia K; Fenton T; Powell CA; Christopherson C; Fletcher CV; Starr SE; Spector SA
J Infect Dis; 2002 May; 185(10):1409-16. PubMed ID: 11992275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
